An episode of acute psychosis can appear to have ended long before the danger of relapse has truly passed. Even after hallucinations, delusions, and severe disorganization begin to subside, the months that follow may remain medically unpredictable. Clinicians must decide how closely to monitor each patient, how intensively to support treatment adherence, and when to intervene before symptoms return. A new prospective study published in Translational Psychiatry examines whether a small molecule in the blood could help answer those questions. The research focuses on copeptin, a biological marker linked to the body’s stress-regulation system, and evaluates its potential to predict relapse during the year after an acute psychotic episode.
The study, led by C.O. Sailer, J. Marian, C. Atila, and colleagues, follows patients prospectively for one year after treatment for acute psychosis. Unlike a retrospective analysis, in which researchers look back at existing records, a prospective follow-up study defines the research question in advance and observes participants over time. That design is particularly important in psychiatry, where symptoms can fluctuate, medication exposure may change, and relapse can be influenced by social stress, sleep disruption, substance use, and treatment discontinuation. By linking an early biological measurement with later clinical outcomes, the researchers are investigating whether copeptin can provide information that is difficult to obtain from a single clinical assessment.
Copeptin is not itself the hormone that directly controls the body’s water balance and stress response. Instead, it is a stable fragment released in equal amounts when the precursor molecule for arginine vasopressin is produced. Arginine vasopressin, also known as antidiuretic hormone, helps regulate fluid concentration in the blood and participates in the hypothalamic-pituitary-adrenal stress network. Because vasopressin is difficult to measure reliably in routine clinical samples, copeptin has become a practical surrogate. It can be measured in blood and may reflect activation of physiological systems involved in stress, cardiovascular regulation, inflammation, and metabolic adaptation.
That biology makes copeptin an intriguing candidate in psychosis research. An acute psychotic episode is not only a disturbance of perception, thought, and behavior; it can also place the body under intense physiological strain. Sleep loss, heightened arousal, altered autonomic activity, medication effects, and the biological consequences of severe distress may all influence stress-related signaling. If copeptin levels differ systematically between patients who later relapse and those who remain stable, the marker could help identify a subgroup requiring closer follow-up. However, a biomarker associated with relapse would not necessarily reveal why relapse occurs. It would be a warning signal, not proof that copeptin causes psychotic symptoms.
The prospective one-year timeframe is clinically meaningful. Relapse often develops after a period of apparent improvement, when patients and families may assume that the crisis has fully passed. Early warning signs can be subtle: disrupted sleep, social withdrawal, suspiciousness, reduced self-care, unusual speech, or a gradual decline in functioning. A blood-based measurement obtained during or shortly after an acute episode could, in principle, complement these observations and support individualized monitoring. The key question is whether copeptin adds predictive value beyond established factors such as previous episodes, medication adherence, duration of untreated psychosis, substance use, comorbid illness, and the severity of the initial presentation.
For a biomarker to become useful in everyday psychiatry, statistical association alone would not be enough. Researchers would need to establish how accurately copeptin separates higher-risk from lower-risk patients, whether there is a clinically meaningful threshold, and how often the test produces false alarms. They would also need to determine whether copeptin remains informative after accounting for dehydration, kidney function, cardiovascular disease, infection, medication, and other conditions that can alter vasopressin-related physiology. A marker that predicts relapse only in a narrowly defined research population may not perform the same way in emergency departments, community clinics, or diverse health systems.
The study’s design also highlights a central challenge in predicting psychiatric relapse: the outcome is shaped by both biology and circumstance. A patient’s risk may change when housing becomes unstable, access to care is interrupted, medication causes intolerable side effects, or family support weakens. Conversely, intensive follow-up and early treatment can prevent a potential relapse from becoming a full psychotic episode, making the outcome appear different from what would have occurred without intervention. These factors must be considered when interpreting any relationship between an initial copeptin measurement and later illness. The marker may reflect vulnerability, current stress, treatment response, or a combination of these processes.
If validated in larger and more diverse cohorts, copeptin could eventually become part of a broader risk-assessment strategy rather than a standalone diagnostic test. Clinicians might combine laboratory data with symptom ratings, digital measures of sleep and activity, medication history, and information from patients and families. Such a model would not replace clinical judgment. Instead, it could offer an additional layer of information at a moment when the patient’s apparent recovery may not fully reveal the likelihood of future deterioration. The greatest value would come from improving the timing and precision of preventive support, not from assigning patients a permanent label.
The findings are therefore relevant beyond one blood test. They reflect a growing effort to connect psychiatry with measurable biological processes while preserving the complexity of mental illness. Psychotic disorders cannot be reduced to a single hormone, protein, or laboratory value, and no biomarker should be presented as destiny. Yet identifying physiological signals associated with relapse could help move care toward earlier intervention and more personalized follow-up. Sailer, Marian, Atila, and their colleagues’ prospective one-year investigation places copeptin within that search, testing whether the body’s stress-response chemistry can offer a forecast of what may happen after an acute psychotic episode. The answer could influence how clinicians monitor recovery, but its ultimate value will depend on replication, clinical validation, and evidence that using the marker improves patient outcomes.
Subject of Research: Copeptin as a potential biological predictor of relapse following an acute psychotic episode.
Article Title: Copeptin as a predictor of relapse in patients with an acute psychotic episode: a prospective 1-year follow-up study.
Article References: Sailer, C.O., Marian, J., Atila, C. et al. “Copeptin as a predictor of relapse in patients with an acute psychotic episode: a prospective 1-year follow-up study.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04374-y
Image Credits: AI Generated
DOI: 10.1038/s41398-026-04374-y
Keywords: copeptin, psychosis, acute psychotic episode, relapse prediction, biomarkers, arginine vasopressin, stress response, psychiatric research, prospective follow-up, personalized psychiatry
